Related Experiment Video
Updated: May 23, 2026
11:31
High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
[Immunotherapy for type 1 diabetes mellitus (DM1)]
Cornelis R van der Torren1, Bart O Roep
1Leids Universitair Medisch Centrum, afd. Immunohaematologie & Bloedtransfusie, Leiden, the Netherlands.
Nederlands Tijdschrift Voor Geneeskunde
|April 13, 2012
Summary
Type 1 diabetes mellitus (DM1) treatments improve but don't cure the condition. Future immunotherapies show promise for protecting insulin-producing cells, but require better efficacy endpoints and biomarker identification.
Area of Science:
- Immunology
- Endocrinology
- Metabolic Diseases
Context:
- Type 1 diabetes mellitus (DM1) management has advanced but struggles to achieve optimal glucose control in most patients.
- Current treatments primarily address disease consequences rather than offering a cure.
- Immunosuppression can slow DM1 progression but does not restore pancreatic beta cell function.
Purpose:
- To evaluate the efficacy of immunotherapy in protecting insulin-producing beta cells in patients with DM1.
- To identify challenges and future directions for DM1 immunotherapy, including the need for improved endpoints and biomarkers.
- To explore novel therapeutic strategies such as antigen-specific vaccination and combination therapies.
Summary:
- Phase 2 immunotherapy studies for DM1 showed promise, but phase 3 trials failed to reproduce results, highlighting patient population and ethnic heterogeneity.
- Effective DM1 treatment requires better efficacy endpoints, biomarkers for disease progression, and response to therapy.
- Future strategies may involve vaccination with beta-cell specific antigens to induce tolerance, potentially combined with biological immunotherapies.
Impact:
- Identifies critical needs for advancing DM1 immunotherapy research, including robust clinical trial design and personalized medicine approaches.
- Suggests potential new therapeutic avenues, such as antigen-specific vaccination and combination immunotherapy, for preserving beta cell function.
- Emphasizes the importance of discussing the risk-benefit profile of immunotherapy side effects with patients.
Related Concept Videos
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...